How did FDMT's revenue and expenses trend in Q4 2024?

4D Molecular Therapeutics (FDMT) reported a 3.85% increase in gross margin to 100% in Q4 2024, with a revenue of $37,000 from the Collaboration and License segment. However, the company also reported a net loss of $49.67 million for the period, indicating that while revenue and gross margin improved, operating expenses were high enough to result in a significant net loss. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |FDMT|FDMT.O|4D Molecular|20240101-2024|Collaboration and License|37000|185| |FDMT|FDMT.O|4D Molecular|20240101-2024|Collaboration and License|36000|185| |FDMT|FDMT.O|4D Molecular|20240101-2024|Collaboration and License|33000|185| |FDMT|FDMT.O|4D Molecular|20240101-2024|Collaboration and License|28000|185| |FDMT|FDMT.O|4D Molecular|20240101-2024|Collaboration and License|28000|185| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |FDMT|FDMT.O|4D Molecular|2024 Q1|-12.966320340283104|-3.2401E7|185| |FDMT|FDMT.O|4D Molecular|2024 Q2|-18.02066450567261|-3.4953E7|185| |FDMT|FDMT.O|4D Molecular|2024 Q3|-327.48634945397816|-4.3843E7|185| |FDMT|FDMT.O|4D Molecular|2024 Q4|-53.86116531920825|-4.9671E7|185| |code|Ticker|Name|Date|Gross Profit Margin|Gross Profit Margin YoY|market_code| |---|---|---|---|---|---|---| |FDMT|FDMT.O|4D Molecular|2024 Q1|100|0|185| |FDMT|FDMT.O|4D Molecular|2024 Q2|100|0|185| |FDMT|FDMT.O|4D Molecular|2024 Q3|100|0|185| |FDMT|FDMT.O|4D Molecular|2024 Q4|100|0|185|